Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Sep 18, 2014	Biocept Granted Patent in China for Its Microfluidic Channel Technology Used to Capture Circulating Tumor Cells Patent Approval Further Strengthens Biocept's IP Position in Personalized Cancer Treatment in East-Asia	View HTML Biocept Granted Patent in China for Its Microfluidic Channel Technology Used to Capture Circulating Tumor Cells 14 KB
Toggle Summary Sep 4, 2014	Biocept to Present at Upcoming Investor Conferences SAN DIEGO, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that Michael Nall, Biocept President and CEO, will be presenting a	View HTML Biocept to Present at Upcoming Investor Conferences 10 KB
Toggle Summary Sep 3, 2014	Biocept Strengthens Its Circulating Tumor Cell IP Position in Europe Key Microfluidic Channel Patent Granted to Biocept in Europe	View HTML Biocept Strengthens Its Circulating Tumor Cell IP Position in Europe 13 KB
Toggle Summary Aug 14, 2014	Biocept Provides Second Quarter Operational Update SAN DIEGO, Aug. 14, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today provided a business update following the recent filing with the US Securities	View HTML Biocept Provides Second Quarter Operational Update 15.5 KB
Toggle Summary Aug 6, 2014	Biocept Appoints Managed Care Expert to Lead Contract and Reimbursement Strategy Quest Diagnostics and GE Healthcare Veteran Amy McNeal Brings Experience to Biocept Team	View HTML Biocept Appoints Managed Care Expert to Lead Contract and Reimbursement Strategy 16.1 KB
Toggle Summary Jun 2, 2014	Biocept Expands Breast Cancer Offering Blood-based OncoCEE-BR™ Platform now Includes Estrogen Receptor Testing SAN DIEGO, June 2, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and circulating tumor cells (CTCs), today	View HTML Biocept Expands Breast Cancer Offering 13.2 KB
Toggle Summary May 19, 2014	Biocept Announces National Sales Force Oncology Sales Specialists to Deploy Blood-Based Cancer Diagnostics Into Physician Practices and Pharmaceutical Development Markets	View HTML Biocept Announces National Sales Force 15.2 KB
Toggle Summary May 7, 2014	Biocept, Inc. Closes $10 Million Term Loan Facility With Oxford Finance LLC SAN DIEGO , May 7, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular diagnostics company specializing in oncology biomarker detection and monitoring through circulating tumor cells (CTCs) and cell-free circulating tumor DNA, today announced that it has closed a loan facility of up	View HTML Biocept, Inc. Closes $10 Million Term Loan Facility With Oxford Finance LLC 16.9 KB
Toggle Summary Apr 28, 2014	Biocept Launches Clinical Research Services for Biomarker Detection in Circulating Tumor DNA SAN DIEGO , April 28, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular diagnostics company specializing in oncology biomarker detection and monitoring through circulating tumor cells (CTCs) and cell-free circulating tumor DNA, today announced the launch of its clinical research	View HTML Biocept Launches Clinical Research Services for Biomarker Detection in Circulating Tumor DNA 16.4 KB
Toggle Summary Mar 24, 2014	Biocept Appoints Commercialization Leader to Implement Global Diagnostic Sales Program Life Technologies and Clarient Veteran Raaj Trivedi Brings Expertise to Biocept Team as Vice President - Commercial Operations	View HTML Biocept Appoints Commercialization Leader to Implement Global Diagnostic Sales Program 14.2 KB

Investor Relations

Press Releases

Contact Biocept, Inc.